X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Before SMITH, HIGGINSON, and ENGELHARDT, Circuit Judges. PER CURIAM: Sandra Hale claims that she suffered injuries when her dentist, Stephen Seder, soaked her dentures in CaviCide disinfecting solution, which is manufactured by Metrex Research Corporation (“Metrex”). She sued Metrex, Seder, the Department of Veterans Affairs, and several others. The only claim Hale asserts against Metrex is its supposed failure to warn and label its product adequately. Metrex moved for judgment on the pleadings, which the district court granted. We affirm. I. Hale visited Seder to be fitted with dentures. Seder directed an assistant to soak her dentures in CaviCide for fifteen minutes, then only briefly rinsed them with tap water before inserting them into her mouth. Hale alleges that, as a result of her exposure to CaviCide, she sustained inflammation, blisters, a chemical burn in her mouth, and liver and kidney damage. CaviCide is a pesticide approved and registered by the Environmental Protection Agency (“EPA”) and regulated by the Federal Insecticide, Fungicide, and Rodenticide Act (“FIFRA”), 7 U.S.C. §§ 136–136y. According to Hale’s complaint, Seder negligently “fail[ed] to follow manufacturer’s instructions for the proper use of CaviCide.” Those instructions warned against Ingestion: Ingestion may cause gastrointestinal disturbances and central nervous system effects such as headache, dizziness, drow- siness and nausea. If swallowed, get medical advice by calling a Poison Control Center or hospital emergency room . . . Skin Contact: Prolonged or repeated exposure may cause mild irri- tation. Rinse skin immediately with plenty of water for 15–20 min- utes. Call a poison control center or doctor for further treatment advice. Chronic Hazards: Prolonged overexposure to ethylene glycol mon- obutyl ether [a component of CaviCide] may affect liver, kidneys, blood, lymphatic system or central nervous system. CaviCide’s label—which was approved by the EPA—also warned that the “product is not to be used on any surface or instrument that (1) is introduced directly into the human body, either into or in contact with the bloodstream or normally sterile areas of the body, or (2) contacts intact mucous membranes[.]“ Hale alleged that “Metrex was negligent, grossly negligent and reckless in failing to warn and label its CaviCide product against” improper use. Metrex moved for judgment on the pleadings under Federal Rule of Civil Pro- cedure 12(c) for four independent reasons. First, Metrex claimed that FIFRA preempts Hale’s state-law failure-to-warn claim. Second, Metrex stated that Hale’s First Amended Complaint concedes that Metrex’s label was adequate, thereby negating an essential element of her failure-to-warn claim. Third, Metrex averred that Texas Civil Practice and Remedies Code § 82.008 creates a presumption of no liability where the defendant complies with labeling requirements, and Hale failed to state any facts to rebut that presumption. Fourth, Metrex asserted that the sophisticated-user doctrine foreclosed its lia- bility as a matter of law. The court granted Metrex’s motion in a one-paragraph order. It held that Hale’s failure-to-warn claim was preempted by FIFRA; it didn’t reach Metrex’s other arguments. It severed Hale’s claims against Metrex and certi- fied its order dismissing those claims as an appealable final judgment. II. Hale contests the judgment on the pleadings. “We review [R]ule 12(c) dismissals de novo.” Great Plains Tr. Co. v. Morgan Stanley Dean Witter & Co., 313 F.3d 305, 312 (5th Cir. 2002). “A motion brought pursuant to Rule 12(c) is designed to dispose of cases where the material facts are not in dispute and a judgment on the merits can be rendered by looking to the sub- stance of the pleadings and any judicially noticed facts.” Machete Prods., L.L.C. v. Page, 809 F.3d 281, 287 (5th Cir. 2015) (brackets omitted). The standard for dismissal under Rule 12(c) is the same as that under Rule 12(b)(6). Edionwe v. Bailey, 860 F.3d 287, 291 (5th Cir. 2017). “To survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to state a claim to relief that is plausible on its face.” Id. Although the district court based its judgment on FIFRA preemption, we “may affirm the district court’s judgment on any grounds supported by the record.” United States v. Dunigan, 555 F.3d 501, 508 n.12 (5th Cir. 2009).[1] A. FIFRA “pre-empts competing state labeling standards” and “any statutory or common-law rule that would impose a labeling requirement that diverges from those set out in FIFRA and its implementing regulations.” Bates v. Dow Agrosciences LLC, 544 U.S. 431, 452 (2005). “[A] state-law labeling requirement is not pre-empted by [FIFRA] if it is equivalent to, and fully consistent with, FIFRA’s misbranding provisions.” Id. at 447. The district court held that because “Metrex’s labeling of CaviCide was approved by the [EPA],” any state-law claims “centering around Metrix’s [sic] failure to provide adequate warnings and instructions on its products are pre- empted by [FIFRA].” Although that result—that FIFRA preempts Texas failure-to-warn claims—may be correct, the reasoning was flawed. That is because “[t]he proper inquiry” for determining whether a state failure-to-warn statute is preempted “calls for an examination of the elements of the common- law duty at issue.” Id. at 445. This court has not yet had occasion to re- examine FIFRA in light of Bates. This case—in which neither the pro se litigant nor her opposition has delineated the state-law elements—presents a bad vehicle for us to delve into that undeveloped preemption issue.[2] Instead, we affirm on an alternative basis. B. Hale’s failure-to-warn claim fails as a matter of law because she admits in her complaint that CaviCide’s label warned against the specific use that allegedly caused her injuries. “In a failure-to-warn case, the plaintiff must show that the warning was defective and that this failure to warn was the producing cause of the plaintiff’s injury.”[3] Generally, “[t]he adequacy of a warning is a question of fact[.]” Alm v. Aluminum Co. of Am., 717 S.W.2d 588, 592 (Tex. 1986). “However, if a warning specifically mentions the circum- stances complained of, then the warning is adequate as a matter of law.”[4] That makes sense, because an essential element of a failure-to-warn claim is that “the absence of a warning or instructions renders the product unreasonably dangerous.” Chandler v. Gene Messer Ford, Inc., 81 S.W.3d 493, 504 (Tex. App.Eastland 2002, pet. denied). Hale concedes that “the use of CaviCide[] to disinfect dentures or any surface or instrument that contacts mucous membranes is prohibited by the CaviCide[] label.” Moreover, Hale maintains that her injuries were caused by Seder’s “failure to follow manufacturer’s instructions clearly printed on the label for the proper use of CaviCide.”[5] Because Hale pleaded that the label expressly warned against the use that caused her injuries, the warning was adequate as a matter of law.[6] The judgment of dismissal is AFFIRMED.

 
Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.

More From ALM

With this subscription you will receive unlimited access to high quality, online, on-demand premium content from well-respected faculty in the legal industry. This is perfect for attorneys licensed in multiple jurisdictions or for attorneys that have fulfilled their CLE requirement but need to access resourceful information for their practice areas.
View Now
Our Team Account subscription service is for legal teams of four or more attorneys. Each attorney is granted unlimited access to high quality, on-demand premium content from well-respected faculty in the legal industry along with administrative access to easily manage CLE for the entire team.
View Now
Gain access to some of the most knowledgeable and experienced attorneys with our 2 bundle options! Our Compliance bundles are curated by CLE Counselors and include current legal topics and challenges within the industry. Our second option allows you to build your bundle and strategically select the content that pertains to your needs. Both options are priced the same.
View Now
April 08, 2025 - April 09, 2025
Chicago, IL

Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies


Learn More
December 02, 2024 - December 03, 2024
Scottsdale, AZ

Join the industry's top owners, investors, developers, brokers and financiers for the real estate healthcare event of the year!


Learn More
December 11, 2024
Las Vegas, NV

This event shines a spotlight on how individuals and firms are changing the investment advisory industry where it matters most.


Learn More

We are seeking two attorneys with a minimum of two to three years of experience to join our prominent and thriving education law practice in...


Apply Now ›

Description: Fox Rothschild has an opening in the New York office for a Real Estate Litigation Associate with three to six years of commerci...


Apply Now ›

Downtown NY property and casualty defense law firm seeks a Litigation Associate with 3+ years' experience to become a part of our team! You ...


Apply Now ›